A method comprising treating a periocular wound in a subject, comprising topically administering to the periocular wound a composition comprising at least one thermoresponsive gel.

A method comprising treating a periocular wound in a subject, comprising topically administering to the periocular wound a composition comprising at least one thermoresponsive gel.

The present disclosure relates to the field of medicines, in particular to the use of IGSF10 in the preparation of a bone tissue regeneration product, especially the use of IGSF10 in combination with BMP in the preparation of a product for promoting bone tissue regeneration. The product includes a periodontal bone defect repair product, a jaw bone defect repair product and/or a skull defect repair product. The new use of IGSF10 of the present disclosure can reduce the effective concentration of BMP without obvious adverse reactions, thereby exploring a method to promote bone tissue regeneration and providing new ideas for the treatment of bone defects.

The disclosure describes new devices and methods for vascularizing devices and methods for implanted diagnostics and therapeutics. The present disclosure provides, in certain embodiments, a device containing a degradable shell and a non-degradable core. In certain embodiments, the non-degradable core can include encapsulated therapeutic cells and/or biosensors, wherein the degradable shell serves as a scaffold for blood vessel growth, resulting in enhanced blood flow to the cells and/or biosensors.

The invention relates to a method for assembling a clay-nanoparticle gel suitable for loading with one or more molecule species such that they are spatially structured therein, and a method for forming a clay-nanoparticle gel comprising one or more spatially structured molecule species. The invention further relates to structured clay nanoparticle gel and their use, for example in treatment.

One aspect of the present disclosure relates to the use of vitrified active agents such as growth factors and/or one or more antimicrobial peptides (AMPs), or other desired active agent, for wound healing as a component of a wound dressing whereby the active agents are vitrified onto one or more polymeric materials, and their release rate regulated by the presence of one or more biodegradable polymeric materials.

The present disclosure provides for a medical device or a substrate coated with polydopamine which is further linked to ligands such as antibodies and/or antibody fragments. The polydopamine coating and the ligands may be linked through a linker such as an organic polymer.

An orthopedic device for implanting between adjacent vertebrae comprising: an arcuate balloon and a hardenable material within said balloon. In some embodiments, the balloon has a footprint that substantially corresponds to a perimeter of a vertebral endplate. An inflatable device is inserted through a cannula into an intervertebral space and oriented so that, upon expansion, a natural angle between vertebrae will be at least partially restored. At least one component selected from the group consisting of a load-bearing component and an osteobiologic component is directed into the inflatable device through a fluid communication means.

Excessive or repeated activation of inflammatory and pro-coagulant mechanisms at the site of tissue injury contributes to the development scar tissue that can lead to intimal hyperplasia and fibrotic disease. It has been established that inhibition of the LYST protein is associated with reduced inflammatory responses and reduced platelet activation at the site of tissue damage. Compositions and methods for inhibition of the expression and function of the LYST protein are described. The compositions and methods can be useful for the modulation of immune processes that contribute to formation of neointima and fibroproliferative disorders by altering macrophage, platelet and natural killer cell function to create a pro-regenerative immune response.

Provided herein are biocompatible hydrogel polymers capable of gelling in vivo comprising a therapeutic agent such as a protein or other biomolecule and kits comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and at least one therapeutic agent. The biocompatible hydrogel polymer is bioabsorbable and releases the therapeutic agent at a target site, avoiding systemic exposure and achieving a controlled delivery.